Press Releases
December 17, 2024
NYMOX Announces Trading Resumed and New Listing on OTCQB Market
Nymox Pharmaceutical Corporation announced today that the Company's stock has resumed trading under the symbol NYMXF on the Over the Counter QB (OTCQB®) Venture Market.
DownloadAugust 30, 2024
Nymox Announces Filing of Annual Report
Nymox Pharmaceutical Corporation is pleased to report that it filed its Annual Report with the Security and Exchange Commission (SEC) on August 29, 2024.
DownloadJuly 18, 2024
Nymox Annual Report
Nymox Pharmaceutical Corporation announced today that its Annual Report is and has been in progress since late February, soon after Nymox received some of its corporate documents withheld by the terminated officers and directors. Unfortunately, this has caused delays beyond the Company’s control in its completion.
DownloadJuly 16, 2024
Nymox Required to Resubmit Application to DKMA
Nymox Pharmaceutical Corporation announced today that its MAA submission to the Danish Medicines Agency (DKMA) has run out of time and in order to continue will be required to extend the MAA application to DKMA by re-submission with a new fee required.
DownloadMarch 27, 2024
Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages
Nymox Pharmaceutical Corporation is pleased to report that the Bahamas Supreme Court has issued a formal Order officially putting an end to the Bahamas litigation brought by terminated ex-employees.
DownloadDecember 27, 2023
Nymox December 27 Message to Shareholders
Nymox Pharmaceutical Corporation is pleased to provide this end-of-the year message to shareholders.
DownloadNovember 30, 2023
Nymox Reports California Court Issues Preliminary Injunction Against Defendants Lanham, Riley, Cutler and Others
Nymox Pharmaceutical Corporation announced today that the California Superior Court, Orange County (OCSC) has issued an order granting Nymox’s preliminary injunction against Randall Lanham, Richard Cutler, Christopher Riley, and the Committee to Restore Nymox Shareholder Value.
DownloadNovember 21, 2023
$250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California Court
Nymox Pharmaceutical Corporation announced today that the California Superior Court, Orange County (OCSC) has accepted on November 18, 2023 Nymox's lawsuit against AscellaHealth and issued a Summons to be served on Ascella.
DownloadNovember 9, 2023
Nymox Pharmaceutical Corporation Sues AscellaHealth For $250 Million
This week, Nymox Pharmaceutical Corporation was forced to file a lawsuit in California Superior Court, Orange County, to protect its shareholders’ interests, as Nymox alleges that a would-be “black knight” competitor that resorted to illegal and unlawful corporate espionage because it could not garner the support of enough Nymox shareholders by legitimate means.
DownloadNovember 3, 2023
NYMOX REPORTS NOTICE: California Court Issued A Temporary Restraining Order Enjoining Lanham, Riley, Cutler And Their Nevada Company After Court Hearing In Santa Ana, California, November 2, 2023
Nymox Pharmaceutical Corporation announced today that a United States court in Orange County, California has ruled against the group of ex-employees and agents Lanham, Riley, and Cutler, as well as their Nevada company.
DownloadNovember 3, 2023
NYMOX REPORTS: Bahamian Court Today Suspends Order of October 3, 2023 Rendering Riley-Lanham and Accomplices Planned Vote Unauthorized
Nymox Pharmaceutical Corporation is pleased to announce that the Bahamian Court (Senior Justice Deborah Fraser) today issued an oral ruling suspending the Ex Parte Order of October 3, 2023 wrongly obtained by the so called activist shareholders led by Mr. Lanham.
DownloadNovember 2, 2023
IMPORTANT MESSAGE TO NYMOX SHAREHOLDERS: NYMOX Cautions Against Unauthorized Improper Shareholder Meeting and Unauthorized Unregistered Solicitations
Nymox Pharmaceutical Corporation warns its shareholders that false and manipulative behavior is involved in attempts to hold what the Company considers an unlawful, unauthorized, and improper "shareholders meeting" that does not have the support of the Company or anyone currently associated with the Company.
DownloadOctober 31, 2023
IMPORTANT NOTICE: NYMOX Cautions Shareholders Not to Take Calls or Participate in Unauthorized Improper Shareholder Meeting
Nymox Pharmaceutical Corporation warns its shareholders that false and manipulative behavior is involved in attempts to hold what the Company believes is an unlawful, unauthorized, and improper "shareholders meeting" that does not have the support of the Company or anyone currently associated with the Company.
DownloadOctober 27, 2023
Notice: Nymox Informs Its Shareholders Not to Take Calls or Participate in An Unauthorized and Improper Shareholder Meeting
The following is Nymox's response to an unauthorized shareholder meeting:
Nymox Pharmaceutical Corporation warns its shareholders that false and manipulative behavior is involved in attempts to hold an unlawful, unauthorized, and improper "shareholders meeting" that does not have the support of the Company or anyone currently associated with the Company.
DownloadOctober 26, 2023
Nymox Reports New NYMOZARFEX Marketing Application is Accepted For Review
Nymox Pharmaceutical Corporation is pleased to announce that the Company's recent submission of Fexapotide Triflutate for the treatment of symptoms of benign prostate enlargement (benign prostatic hyperplasia, referred to as BPH) has been validated by the U.K. authorities, at U.K. Medicines & Healthcare products Regulatory Agency (MHRA).
DownloadSeptember 25, 2023
Nymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH
Nymox Pharmaceutical Corporation is pleased to announce today that a new formal submission has been made by the Company in the U.K. for Nymozarfex (TM) for the treatment of benign prostatic hyperplasia (BPH).
DownloadAugust 29, 2023
Nymox Reports Completion of $2 Million Private Placement
Nymox Pharmaceutical Corporation is pleased to announce the completion of its recently reported private placement of USD 2 million.
DownloadAugust 2, 2023
Nymox Announces $2 Million Private Placement
Nymox Pharmaceutical Corporation is pleased to announce an investment of US $2.0 million for 2 million shares at the price of $1.00 per share with 500,000 warrants priced at $2.00.
DownloadJuly 31, 2023
Nymox's 3-month ex-CFO was Awarded an Unauthorized and Undisclosed Treasury Directive for 100,000 Shares of Nymox Stock Without the Knowledge or Approval of the Nymox Board or Nymox’s CEO
Nymox Pharmaceutical Corporation reports that Chris Riley, who was terminated in June of this year after only 3 months as CFO was awarded on March 13, 2023 an unauthorized and undisclosed Treasury Issuance Request (the “Treasury Directive”) for 100,000 shares of Nymox stock, independently executed by the Company's ex-legal counsel Randall Lanham without the knowledge, disclosure, or approval of the independent Board members, or the Company CEO.
DownloadJuly 25, 2023
Nymox Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results
Nymox Pharmaceutical Corporation is pleased to announce today important new long-term clinical trial results from the Company's 146 patient NX03-0040 NYMOZARFEX (TM) U.S. study for low grade localized prostate cancer.
DownloadJuly 18, 2023
Nymox Reports on U.S. Patent Issuances
Nymox Pharmaceutical Corporation is pleased to announce the Issuances of several of its important U.S. patents for NYMOZARFEX.
DownloadJuly 13, 2023
Nymox Update
Nymox Pharmaceutical Corporation is providing additional information concerning recent changes in the Company’s board of directors (the “Board”) and management, as well as additional information regarding the Company’s conclusion that a potential transaction was not in the best interests of the Nymox and its shareholders.
DownloadJuly 12, 2023
Nymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of Nymox
Nymox Pharmaceutical Corporation is pleased to announce the appointment of Patrick Doody as Nymox Vice President, General Counsel, and Member of Nymox Board of Directors.
DownloadJuly 7, 2023
Nymox Update
Nymox Pharmaceutical Corporation is providing information to address requests it has received for further information concerning recent changes to the Company’s Board of Directors (“Board”) and the Company’s management.
DownloadJuly 5, 2023
Nymox Delisting from NASDAQ
Nymox Pharmaceutical Corporation today received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq, and hence the Company's shares will be suspended from trading on NASDAQ at the open of business on July 7, 2023. Nymox shares will be moved to the OTC market. The mechanics of trading the stock remain the same, as do the Company's business fundamentals.
DownloadMay 10, 2023
Nymox Provides Current Update
Nymox Pharmaceutical Corporation is pleased to provide a mid-2nd quarter update on ongoing activities
DownloadApril 3, 2023
Nymox Provides Corporate Update
Nymox Pharmaceutical Corporation is pleased to provide a current update on the Company's ongoing projects.
DownloadMarch 21, 2023
Nymox Announces Appointment of Christopher R. Riley as Chief Financial Officer
Nymox Pharmaceutical Corporation is pleased to announce the appointment of Christopher R. Riley as Chief Financial Officer (CFO) of Nymox.
DownloadMarch 15, 2023
Nymox Officially Granted Extension to Regain Listing Requirements
Nymox Pharmaceutical Corporation has officially been granted by NASDAQ an additional period until July 3, 2023 to regain compliance with NASDAQ listing requirements, the Company reported today.
DownloadFebruary 15, 2023
Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review
Nymox Pharmaceutical Corporation is pleased to announce that the Company's recent submission of Fexapotide Triflutate for the treatment of symptoms of benign prostate enlargement (benign prostatic hyperplasia, referred to as BPH) has been validated by the Denmark authorities, and the formal review process has now started.
DownloadJanuary 6, 2023
NYMOX Appeals Deficiency Letter
Nymox Pharmaceutical Corporation reports that on January 4, 2023 the Company received a deficiency letter from The Nasdaq Stock Market (“Nasdaq”) stating that, because the Company’s common stock continues to trade at less than $1.00 per share, the Company has not regained compliance with the Rule 5550(a)(2) requiring a minimum bid price, and because the Company’s Stockholders’ equity was less than $5,000,000 as of September 30, 2022, the Company is not eligible for a second 180 day period.
DownloadDecember 5, 2022
NYMOX Announces New Marketing Submission for NYMOZARFEXTM for BPH
Nymox Pharmaceutical Corporation is pleased to announce today that a new formal submission has been made by the Company in Europe for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH).
DownloadNovember 25, 2022
May 2023 Market Cap Requirement Update
Nymox Pharmaceutical Corporation reports that on November 18, 2022 the Company received a deficiency letter from NASDAQ stating the Listing Rules require listed securities to maintain and minimum market value of listed securities of $35 million.
DownloadSeptember 13, 2022
NYMOX Provides Current Update
Nymox Pharmaceutical Corporation Is pleased to provide a current update on business developments.
DownloadJuly 15, 2022
NYMOX Updates Shareholders
Nymox Pharmaceutical Corporation today announced an update to its shareholders regarding progress in the Company business activities.
DownloadJuly 14, 2022
NYMOX Receives Deficiency Letter from NASDAQ
Nymox Pharmaceutical Corporation reports that on July 7, 2022 the Company received a deficiency letter from NASDAQ stating that the Company is no longer in compliance with Nasdaq Listing Rule 5550(a)(2).
DownloadMay 23, 2022
NYMOX Receives RTF letter from FDA
Nymox Pharmaceutical Corporation reports today that it has received a Refusal to File (“RTF”) letter from FDA on Friday May 20th at 2:48 pm EST, with regard to the Company's New Drug Application (“NDA”) for Fexapotide Triflutate.
DownloadApril 4, 2022
NYMOX ANNOUNCES CLOSING OF $6.4 MILLION FINANCING
Nymox Pharmaceutical Corporation is pleased to announce that it has closed its $6.4 million financing announced in its filing of March 22 with institutional and accredited investors consisting of 3,878,789 common shares at a purchase price of $1.65 per share, sold pursuant to a registered direct offering.
DownloadMarch 18, 2022
Nymox Announces $5 Million Registered Direct Offering
Nymox Pharmaceutical Corporation today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of 3,030,304 common shares at a purchase price of $1.65 per share in a registered direct offering for gross proceeds of approximately $5 million before deducting placement agent fees and expenses.
DownloadMarch 3, 2022
NYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate
Nymox Pharmaceutical Corporation is pleased to announce today that it has submitted the Company’s New Drug Application (NDA) to the FDA for Fexapotide Triflutate to seek marketing approval in the U.S. for Fexapotide Triflutate for the treatment of men with benign prostatic hyperplasia (BPH).
DownloadDecember 13, 2021
NYMOX SHAREHOLDER UPDATE
Nymox Pharmaceutical Corporation is pleased to announce that it has completed all the Company’s required tasks in preparation for its planned upcoming regulatory submission for Fexapotide Triflutate for the treatment of BPH.
DownloadNovember 15, 2021
NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference
Nymox Pharmaceutical Corporation is pleased to report today that it will be presenting at the Torrey Hills Capital Emerging Growth Conference this week.
DownloadOctober 11, 2021
NYMOX Provides Current Update
Nymox Pharmaceutical Corporation is pleased to report today a one-month update to shareholders as a follow-up to the September communication. The Company reinforces that its completion tasks for the important Fexapotide filing have advanced as anticipated and that substantial progress has ensued.
DownloadSeptember 10, 2021
NYMOX Provides Shareholder Update
Nymox Pharmaceutical Corporation is pleased to provide an update on the Company's progress with its BPH treatment product Fexapotide Triflutate.
DownloadMay 6, 2021
Nymox Announces Date for Fexapotide Filing
Nymox Pharmaceutical Corporation is pleased to announce that it will be filing for marketing approval of Fexapotide Triflutate for BPH before the end of the summer, on or before 15 September 2021.
DownloadApril 28, 2021
NYMOX ANNOUNCES $8,000,000 PRIVATE PLACEMENT
Nymox Pharmaceutical Corporation today announced it has entered into a definitive agreement with institutional investors in a private placement...
DownloadMarch 29, 2021
Nymox Provides New Update on Regulatory Activities
Nymox Pharmaceutical Corporation is pleased to provide the latest update on the Company's regulatory filing preparation activities.
DownloadNovember 16, 2020
Nymox Provides Update on Regulatory Filing Activities
Nymox Pharmaceutical Corporation is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutate (FT), Nymox's first in class lead product for the treatment of benign prostatic hyperplasia (BPH). Substantial progress has been made and there are no material changes to the content of the planned applications.
DownloadAugust 12, 2020
Nymox Announces $9 Million Registered Direct Offering
Nymox Pharmaceutical Corporation today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of shares of its common stock.
DownloadJuly 28, 2020
NYMOX Provides Current Update on Key Company Developments
Nymox Pharmaceutical Corporation is pleased to report current updates on the Company's most important ongoing developments.
DownloadJune 19, 2020
Nymox Announces Updates in Regulatory Submissions For Fexapotide Treatment For Prostate Enlargement
Nymox Pharmaceutical Corporation is very pleased to report that key steps in its regulatory submission preparations have been completed and the project is firmly on-track.
DownloadApril 21, 2020
Nymox Announces Important New Patent Developments
Nymox Pharmaceutical Corporation is pleased to announce the recent allowances of 4 new different US and international patents concerning the Company's prostate enlargement and prostate cancer treatments.
DownloadFebruary 24, 2020
Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Journal of Urology
Nymox Pharmaceutical Corporation is pleased to announce that a new peer review report was published today in the World Journal of Urology, documenting the successful long-term clinical trial results after Fexapotide Triflutate treatment for early stage prostate cancer.
DownloadFebruary 6, 2020
Nymox Announces New Appointment of Russell Thomson Ph.D. as Nymox Vice President of Quality and Regulatory Affairs
Nymox Pharmaceutical Corporation is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of Nymox Vice President of Quality and Regulatory Affairs. Dr Thomson is an authority in the field of Quality Assurance and Control in the chemical and pharmaceutical industries.
DownloadJanuary 28, 2020
Nymox Provides Update on Current Corporate Activities and Milestones
Nymox Pharmaceutical Corporation is pleased to provide a current January 2020 update on several important corporate activities and achievements since the last update in October 2019.
DownloadJanuary 6, 2020
Nymox Announces New Peer Review Article on Fexapotide Pharmaco-Ablation Experimental Studies Published in Research and Reports in Urology
Nymox Pharmaceutical Corporation is pleased to report a new peer review research report has been published on experimental studies of the Company's Fexapotide Triflutate treatment for prostate enlargement (BPH) and low grade prostate cancer. The article is entitled "Fexapotide triflutate induces selective prostate glandular pharmaco-ablation in the rat" and it is published in Research and Reports in Urology.
DownloadOctober 21, 2019
Nymox Reports on Newly Issued Patents and Corporate Developments
Nymox Pharmaceutical Corporation is pleased to report very positive fundamental news, that the Company has received several new additional United States, European, and other jurisdictional formal patent issuances covering Fexapotide Triflutate and its use for prostate and urinary tract disorders.
DownloadJune 25, 2019
Nymox End of Q2 New Investor Presentation on Website
Nymox Pharmaceutical Corporation is pleased to provide an up-to-date investor communication presentation posted on the Nymox website today as the end of second quarter update for shareholders.
DownloadApril 16, 2019
Nymox Reports Pre-NDA CMC Meeting with the FDA
Nymox Pharmaceutical Corporation today announced that it has held its pre-New Drug Application (NDA) Chemistry Manufacturing and Controls (CMC) meeting with the US Food and Drug Administration (FDA) regarding its lead product candidate Fexapotide Triflutate.
DownloadMarch 21, 2019
Nymox Teleconference Monday, March 25 10:00 a.m. EDT
Nymox will hold a teleconference for shareholders on Monday, March 25 at 10:00 a.m. Eastern Daylight Time (EDT). Management will provide an update on the current status of the Company's business activities including regulatory filings, and after the update will respond to calls from shareholders and interested parties.
DownloadMarch 19, 2019
Nymox Announces Appointment of Mark Staples PhD as Vice President of Chemistry, Manufacturing and Controls (CMC)
Nymox Pharmaceutical Corporation is pleased to announce that Mark Staples PhD has joined Nymox as Vice President for Chemistry, Manufacturing, and Controls (CMC).
DownloadMarch 13, 2019
Nymox Announces Appointment of Russell Thomson Ph.D. as Director of Quality and EU Qualified Person for Company's Manufacturing Operations
Nymox Pharmaceutical Corporation is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC, as the Company's Director of Quality and EU Qualified Person, for all of Nymox's Chemistry, Manufacturing and Controls Operations.
DownloadMarch 11, 2019
Nymox to Host Investor Teleconference
Management will discuss the Company's current business progress with an update on its regulatory submission activities in the US and EU. Further details re time and coordinates and information for the call will be provided prior to the teleconference.
DownloadJanuary 15, 2019
New Peer Review Article Entitled “Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia” Published in Therapeutic Advances in Urology
Nymox Pharmaceutical Corporation reports today that a new peer review article has been published in Therapeutic Advances in Urology.
DownloadDecember 19, 2018
2018: A Year of Achievements for NYMOX
Following the Nymox Annual General Meeting yesterday (December 18, 2018), Nymox management discussed many significant 2018 events and commented on key operational milestones coming up in 2019.
DownloadOctober 11, 2018
Corporate Update To Shareholders: Preparatory Work For Regulatory Filings On Track
Following many shareholder enquiries in recent weeks Nymox Pharmaceutical Corporation is pleased to provide shareholders with a brief update on its core activities.
DownloadOctober 9, 2018
Nymox Reports 78 Month Results From Biopsy and Surgery Confirmed Prospective Randomized NX03-0040 Prostate Cancer Study of Fexapotide Triflutate: Gleason Grade Progression Reduced by 81% Overall and Fexapotide 15mg Minimal Treatment Leads to 73% Long-Term Reduction in Incidence of Associated Prostate Cancer Surgery and Radiotherapy
Nymox Pharmaceutical Corporation is pleased to announce today important new long-term clinical trial results from the Company’s 146 patient Phase IIb NX03-0040 Fexapotide (FT) U.S. study for low grade localized prostate cancer.
DownloadOctober 3, 2018
Nymox Reports Safety Benefits of Fexapotide Treatments for Prostate Cancer and Benign Prostatic Hyperplasia
Nymox Pharmaceutical Corporation reported today that after long-term safety assessments of repeated Fexapotide Triflutate (FT) intraprostatic injections, there have been no identifiable risks or serious side effects or adverse events identified associated or linked with the drug.
DownloadJuly 2, 2018
Nymox Announces Expanded Marketing Plans
Nymox Pharmaceutical Corporation announced today that following the recently announced increased manufacturing capabilities, the Company has formally decided to expand its European marketing plans for Fexapotide Triflutate (FT) to all countries in the European Community.
DownloadJune 7, 2018
NYMOX Successfully Achieves Manufacturing Scale-Up
Nymox Pharmaceutical Corporation is pleased to report that manufacturing scale-up milestones have been reached for the Company’s lead compound Fexapotide Triflutate (FT).
DownloadMay 22, 2018
Fexapotide Triflutate Pivotal Phase 3 Study Results Presented and Discussed at American Urological Association Annual Meeting in San Francisco
Nymox Pharmaceutical Corporation is pleased to report on a successful symposium discussing Nymox’s lead product candidate Fexapotide Triflutate (FT) as a novel therapeutic option in BPH at the Annual Meeting of the American Urological Association in San Francisco, this past weekend.
DownloadMay 11, 2018
Nymox’s Fexapotide Featured in Broadcast of Grand Rounds in Urology
Nymox Pharmaceutical Corporation is pleased to announce that an informative interview and presentation was released on Grand Rounds in Urology, a highly respected and authoritative urologic professional community, and host of international conferences and symposia that bring together the top thought leaders in the treatment of urologic disease, with meetings that focus on current best treatment practices as well as future trends and directions.
DownloadMay 7, 2018
Nymox Announces Relocation of Company Headquarters to Switzerland
Nymox Pharmaceutical Corporation is pleased to announce that it has initiated the process of relocating the Company Headquarters from Nassau, Bahamas to Zug in Switzerland.
DownloadMay 2, 2018
Nymox Announces Fexapotide Drug Symposium at AUA Annual Meeting San Francisco May 20
Nymox Pharmaceutical Corporation is pleased to announce that there will be a Symposium on the Company’s lead drug Fexapotide held at the Annual Meeting of the American Urological Association on May 20 in San Francisco.
DownloadApril 12, 2018
Nymox Announces $16.25 Million Equity Financing With Qualified Long-Term Investors
Nymox Pharmaceutical Corporation is pleased to announce today that the Company has successfully secured $16.25 million in new equity capital with several professional high net worth investors.
DownloadApril 10, 2018
New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of Urology
A new online published commentary about Nymox’s Fexapotide 2018 clinical trial results publication in World Journal of Urology has newly appeared today on UroToday in its “Beyond the Abstract” section, along with the abstract of the World Journal of Urology article.
DownloadMarch 1, 2018
Symposium and Panel Discussion on Nymox’s Fexapotide To Be Held at American Urological Association Mid-Atlantic Section Annual Meeting on March 3
Nymox Pharmaceutical Corporation is pleased to report that a Symposium on Fexapotide Triflutate studies will be held at the Annual Meeting of the American Urological Association Mid-Atlantic Section, in Amelia Island FL March 3.
DownloadFebruary 5, 2018
Nymox Announces US NDA for Fexapotide for BPH
Nymox Pharmaceutical Corporation announced today that the Company will submit a New Drug Application (NDA) for Fexapotide Triflutate for the treatment of BPH in the US.
DownloadJanuary 30, 2018
Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology
Nymox Pharmaceutical Corporation reports today that the results of Phase 3 clinical studies of Fexapotide Triflutate undertaken from 2009-2016 are now published in World Journal of Urology.
DownloadJanuary 22, 2018
Nymox Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. Men
Nymox Pharmaceutical Corporation reported today top-line 5-year results from Nymox’s U.S. Study NX03-0040. Study NX03-0040 was undertaken starting in 2012 at 44 investigational sites across the U.S. comprising a highly representative sample of 146 men with the biopsy confirmed diagnosis of T1c prostate cancer, which is the most common type of low grade localized prostate cancer.
DownloadNovember 27, 2017
Nymox Fexapotide Symposium and Panel Discussion at American Urological Association South Central Sectional Annual Meeting in Naples FL
Nymox Pharmaceutical Corporation is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, South Central Section in Naples, November 27.
DownloadNovember 16, 2017
Nymox Fexapotide Symposium and Panel Discussion at American Urological Association North Central Sectional Annual Meeting in Scottsdale
Nymox Pharmaceutical Corporation is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, North Central Section in Scottsdale, November 15
DownloadNovember 10, 2017
Symposium and Panel Discussion on Nymox’s Fexapotide To Be Held at American Urological Association North Central Section Annual Meeting in Scottsdale AZ November 15
Nymox Pharmaceutical Corporation is pleased to report that a Symposium on Fexapotide Triflutate studies will be held at the Annual Meeting of the American Urological Association North Central Section, in Scottsdale AZ next week.
DownloadNovember 7, 2017
Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana
Nymox Pharmaceutical Corporation is pleased to report on the two data presentations which were held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, New York Section in Havana, November 6.
DownloadOctober 26, 2017
Nymox Announces Two Data Presentations for Company’s BPH Drug at New York American Urological Association Meeting November 6
Nymox Pharmaceutical Corporation is pleased to announce that two data presentations of the Company’s new drug Fexapotide Triflutate will be held at the November meeting of the American Urological Association, New York Section.
DownloadOctober 13, 2017
Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah
Nymox Pharmaceutical Corporation is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, Northeast Section in Savannah, October 12 at 4 pm.
DownloadOctober 10, 2017
Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12
Nymox Pharmaceutical Corporation is pleased to report on the Symposium on Fexapotide Triflutate studies to be held at the Annual Meeting of the American Urological Association Northeastern Section, in Savannah GA this week.
DownloadSeptember 25, 2017
Nymox Announces October 12 Symposium for Company’s BPH Drug at American Urological Association Meeting
Nymox Pharmaceutical Corporation is pleased to announce that an important large symposium and panel assessment of the Company’s new drug Fexapotide Triflutate will be held at the October meeting of the American Urological Association, Northeast Section.
DownloadSeptember 14, 2017
Nymox Announces Validation by the European Member States of European Marketing Authorization Application for Fexapotide Triflutate for Benign Prostatic Hyperplasia
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce today that the European Member States for Nymox’s Marketing Authorization Application (MAA) for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH, prostate enlargement) have accepted the Company’s MAA.
DownloadSeptember 11, 2017
AUA Meeting in Florida September 16 Postponed Due to Hurricane
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) The September 16 AUA Meeting in Amelia Island, Florida has been postponed due to the hurricane disaster in Florida.
DownloadAugust 9, 2017
Nymox Announces Private Placements of $3 Million
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce recent completion of private placements with proceeds totaling US $3.0 million.
DownloadAugust 7, 2017
Nymox Announces Symposium for Company’s BPH Drug at American Urological Association Meeting in September
Nymox Pharmaceutical Corporation is pleased to announce that an important large symposium and panel assessment of the Company’s new drug Fexapotide Triflutate will be held at the September meeting of the American Urological Association, MidAtlantic Section.
DownloadMay 31, 2017
Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical Trials
Nymox Pharmaceutical Corporation is pleased to announce statistically significant clinical trial results showing that the Companys prostate enlargement (BPH) and prostate cancer drug Fexapotide Triflutate produced clinically important improvements in sexual function in first-line patients who received Fexapotide in the Companys U.S. long-term clinical trials.
DownloadMay 10, 2017
NYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDT
Nymox Pharmaceutical Corporation will hold a teleconference call for shareholders today May 10 at 4:30 EDT. The call in number is 1-888-424-8151 and the passcode is 7826703# (for Canada please use 1-888-465-5079).
DownloadMay 8, 2017
NYMOX Files For Approval of First In Class Prostate Drug in Europe: Company To Hold Teleconference Wednesday May 10 at 4:30 EDT
Following Nymoxs announcement of the Companys filing for marketing approval of Fexapotide Triflutate for enlarged prostate (BPH) in Europe, Nymox is pleased to announce a teleconference with shareholders at 4:30 p.m. EST on Wednesday May 10, 2017.
DownloadMay 3, 2017
Nymox Files For Marketing Approval For Fexapotide Triflutate in Europe
May 3, 2017: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce today that the Company has filed to seek approval for marketing authorization for Fexapotide Triflutate in five European countries, comprising the Netherlands, the UK, Germany, France and Spain.
DownloadMarch 29, 2017
Nymox Provides Update on Fexapotide Development
Nymox Pharmaceutical Corporation provided an update today on the Companys development activities for Fexapotide Triflutate, its new drug for prostate enlargement.
DownloadNovember 29, 2016
Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy
Nymox Pharmaceutical Corporation is pleased to announce that new Phase 3 prospective randomized clinical trial results have confirmed that patients who received fexapotide as their initial treatment for BPH (prostate enlargement) had superior efficacy results as early as 10 days compared to control patients who received placebo or who had prior history of other BPH medical treatments.
DownloadOctober 11, 2016
Nymox Reports Successful New Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results: Lasting Symptomatic Improvement Up To 6 Years After Single Repeated Treatment
Nymox Pharmaceutical Corporation is pleased to announce successful new study results from the long-term repeated injection group from the U.S. Phase 3 trials for fexapotide, the Companys lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer.
DownloadAugust 29, 2016
Nymox’s New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show
Nymox Pharmaceutical Corporation lead drug fexapotide which has been in development for over a decade and which has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers…
DownloadAugust 24, 2016
Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery
Nymox Pharmaceutical Corporation is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Companys lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer.
DownloadAugust 17, 2016
Nymox Announces Private Placements of $2.24 Million
Nymox Pharmaceutical Corporation is pleased to announce that it has recently closed private placements and other investments in the Company for a total of $2.24 million.
DownloadAugust 11, 2016
Nymox Announces Prostate Drug Progress
Nymox Pharmaceutical Corporation is pleased to announce major progress in the evidence for the safety and efficacy of fexapotide, the Companys Phase 3 drug in the final stages of development for prostate enlargement (BPH) and for low grade prostate cancer.
DownloadJune 22, 2016
Nymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study of 995 U.S. Middle-Aged and Elderly Men Without Cancer
Nymox Pharmaceutical Corporation announced today results from the Companys 7 year prospective placebo controlled double blind studies of treatment of 995 U.S. men with the Companys lead drug fexapotide.
DownloadFebruary 9, 2016
Nymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study
Nymox Pharmaceutical Corporation today announced results from the completion of the Companys U.S. 40 month (18 month outcomes) localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207).
DownloadFebruary 4, 2016
Nymox Announces Additional $2.1 Million Equity Financing
Nymox Pharmaceutical Corporation announced today private placement equity investment of US$2.1 Million.
DownloadDecember 17, 2015
Nymox Files Current Financial Statements
Nymox Pharmaceutical Corporation is pleased to announce that today the Company has filed its third quarter 2015 and restated second quarter 2015 financial statements.
DownloadDecember 17, 2015
Nymox Provides Update From Shareholders Annual General Meeting December 16
Nymox Pharmaceutical Corporation is pleased to report an update on the Corporations business as of December 16, 2015.
DownloadOctober 29, 2015
Nymox Reports Results of Prospective Cross-Over Study of Fexapotide Treatment for Prostate Cancer
Nymox Pharmaceutical Corporation reported today that long-term randomized cross-over data from the Companys trial of fexapotide triflutate for low grade localized prostate cancer has shown statistical significance in efficacy compared to controls.
DownloadAugust 4, 2015
Nymox Announces Change of Company’s Domicile and Head Office
Nymox Pharmaceutical Corporation is pleased to announce that the Company has received formal approvals for its change of domicile to the Bahamas effective July 31, 2015.
DownloadJuly 30, 2015
Nymox Announces Appointment of James G. Robinson to Board of Directors
Nymox Pharmaceutical Corporation is pleased to announce that the Company has newly appointed James G. Robinson to the Board of Directors.
DownloadJuly 28, 2015
Nymox July 27 Webcast of New BPH Clinical Trial Results Posted Today Online
(July 28, 2015) Nymox’s (NASDAQ:NYMX) July 27th webcast of news and discussion by experts of the Company’s new clinical trial results can be viewed at http://limelightdc.com/clientarea/nymox_investor_webcast_7_15/player_vod.html. The link is also available at the Company’s website.
DownloadJuly 27, 2015
Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans to File For Regulatory Approvals For Fexapotide Triflutate (NX-1207).
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that the Companys U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo.
DownloadJuly 16, 2015
Nymox Appoints Cutler & Co. as Auditor
July 16, 2015: On July 15, 2015, the Board of Directors of Nymox Pharmaceutical Corporation (NASDAQ: NYMX) approved the engagement of Cutler & Co., LLC to serve as the Company’s new independent registered public accounting firm to replace KPMGLLP.
DownloadJuly 13, 2015
Nymox Announces Appointment of Erik Danielsen as CFO
Nymox Pharmaceutical Corporation is pleased to announce the appointment of Erik Danielsen as Chief Financial Officer of the Company.
DownloadJune 16, 2015
Nymox Announces $850,000 Financing
Nymox Pharmaceutical Corporation is pleased to announce that it has recently completed financing for a total of $850,000 at prices of $1.25-$1.66.
DownloadMay 15, 2015
Nymox Reports First Quarter 2015 Financial Results
Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2015 prepared in accordance with International Financial Reporting Standards.
DownloadApril 20, 2015
Nymox Announces New Prostate Cancer Clinical Trial Results
Nymox Pharmaceutical Corporation announced today long-term clinical trial results from the Companys NX-1207 prostate cancer study NX03-0040.
DownloadApril 1, 2015
Nymox Announces Phase 3 BPH Studies
Nymox Pharmaceutical Corporation announced today that the Company is undertaking further analyses of its pivotal U.S. Phase 3 studies of NX-1207 for prostate enlargement (BPH).
DownloadMarch 31, 2015
Nymox Reports 2014 Financial Results
March 31, 2015: Nymox Pharmaceutical Corporation announced today its financial results for the year ended December 31, 2014 prepared in accordance with International Financial Reporting Standards.
DownloadMarch 19, 2015
Nymox Announces Private Placements of US $400,000
March 19, 2015: Nymox Pharmaceutical Corporation announced today recent private placements of 883,058 shares, with total proceeds of US$400,000.
DownloadDecember 14, 2014
Nymox Announces $1.07 Million Financing
December 18, 2014: Nymox Pharmaceutical Corporation announced today the closing of U.S. $1.07 million in financing, consisting of a 3 year term convertible debenture at 6% with conversion at $0.53.
DownloadNovember 14, 2014
Nymox Reports Third Quarter 2014 Financial Results
November 14, 2014: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the third quarter of 2014.
DownloadNovember 2, 2014
Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02- 0018 Fail to Meet Primary Efficacy Endpoints
November 2, 2014: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company’s two Phase 3 U.S. studies of NX-1207 for the treatment of BPH, NX02-0017 and NX02-0018, failed to meet their primary efficacy endpoints.
DownloadSeptember 11, 2014
Nymox Reports Second Quarter 2014 Financial Results
August 11, 2014: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today its financial results for the second quarter of 2014.
DownloadSeptember 10, 2014
Nymox Announces Positive Prostate Cancer 8 Month Clinical Trial Results
September 10, 2014: Nymox announced today new positive outcome results from the Companys ongoing prospective NX03-0040 trial of NX-1207 for the treatment of low grade localized prostate cancer.
DownloadJuly 22, 2014
Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH
DownloadJuly 15, 2014
Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study
DownloadJune 17, 2014
Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207
June 17, 2014: Nymox is pleased to report new data supporting the positive sexual functional preservation profile of NX-1207, the Companys lead compound in Phase 3 development for the treatment of prostate enlargement (BPH or benign prostatic hyperplasia) and Phase 2 development for localized prostate cancer. A detailed study of prostate tissues from men who had received intraprostatic injections of NX-1207 2.5 mg or 15 mg found that nervous tissues in the prostate after treatment were left intact and showed no damage. These new results showing that NX-1207 is nerve-sparing add to the considerable body of evidence that treatment with NX-1207 does not lead to the debilitating sexual side effects often associated with existing prostate treatments.
DownloadJune 11, 2014
Nymox Reports Positive New Safety Study Data For Phase 3 BPH Drug
June 11, 2014: Nymox is pleased to announce new clinical data supporting the positive safety profile of NX-1207, the Companys lead compound in late Phase 3 testing for prostate enlargement (BPH or benign prostate hyperplasia). Recent pharmacokinetic studies using a newly developed highly sensitive blood test for NX-1207 have shown that the drug is undetectable in the blood post-injection, providing strong evidence that the drug, once injected into the prostate, remains confined to the prostate and thus unable to affect other organs such as the liver, kidneys, heart, or testes.
DownloadMay 21, 2014
Nymox Reports New Results on Favorable Side Effect Profile of NX-1207 Treatment
May 21, 2014: Nymox is pleased to report new positive data confirming the advantageous side effect profile of the Companys lead compound NX-1207. Results from the Brief Male Sexual Function Questionnaire (BMSF) in the Companys recently completed NX03-0040 trial of NX-1207 2.5 mg and 15 mg for the treatment of low grade localized prostate cancer indicate that targeted treatment with NX-1207 at either dose had no significant effect on reported sexual function score post-treatment.
DownloadMay 15, 2014
Nymox Reports First Quarter 2014 Financial Results
May 15, 2014: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the first quarter of 2014.
DownloadMay 13, 2014
Nymox Reports Positive Results Showing That NX-1207 Treatment for Prostate Cancer Does Not Affect Testosterone Levels
DownloadMay 8, 2014
Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH
DownloadMay 6, 2014
Nymox Announces Positive New Prostate Cancer Clinical Trial Results
DownloadApril 30, 2014
Nymox Reports Top-Line Results for Localized Prostate Cancer Study
April 30, 2014: Nymox is pleased to report top-line results from the companys 146 patient NX03-0040 Phase 2 U.S. prostate cancer study. The results from the study indicate an overall benefit in terms of reduced progression in patients with low grade localized (T1c) prostate cancer treated with a single injection of NX-1207 into the area of the prostate where cancer was found. Consistent with earlier clinical trial experience with NX-1207, there were no significant safety issues or side effects associated with the drug in the new study.
DownloadMarch 14, 2014
Nymox Reports 2013 Financial Results
March 14, 2014: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the year ended December 31, 2013.
DownloadFebruary 5, 2014
Nymox Announces Appointment of Andre Monette
February 5, 2014: Nymox is pleased to announce the appointment of Andre Monette as Chief Financial Officer of the Company.
DownloadJanuary 28, 2014
Nymox Provides Update on NX-1207 Phase 3 BPH and Phase 2 Prostate Cancer Clinical Trial Activities
DownloadJanuary 13, 2014
Nymox Closes Recruitment for NX-1207 Phase 2 Prostate Cancer Trial
January 13, 2014: Nymox today announced that recruitment is being closed for the Companys Phase 2 study of NX-1207 for low risk localized prostate cancer (NX03-0040) and that enrollment will be formally completed shortly. Initial top line study results are expected to be available approximately 6-8 weeks after completion of enrollment.
Download